CO5261637A1 - MALE ANTI-CONCEPTIVE FORMULATION UNDERSTANDING NORETISTERONE - Google Patents
MALE ANTI-CONCEPTIVE FORMULATION UNDERSTANDING NORETISTERONEInfo
- Publication number
- CO5261637A1 CO5261637A1 CO01010963A CO01010963A CO5261637A1 CO 5261637 A1 CO5261637 A1 CO 5261637A1 CO 01010963 A CO01010963 A CO 01010963A CO 01010963 A CO01010963 A CO 01010963A CO 5261637 A1 CO5261637 A1 CO 5261637A1
- Authority
- CO
- Colombia
- Prior art keywords
- progestin
- formulation according
- formulation
- dose
- sufficient
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una formulación anticonceptiva masculina CARACTERIZADA PORQUE comprende una cantidad eficaz de una progestina, donde dicha progestina posee propiedades tanto androgénicas como estrogénicas. Una formulación de acuerdo con la reivindicación 1 CARACTERIZADA PORQUE la progestina es noretisterona (NET) o sus derivados, tales como sus ésteres carboxílicos, en particular su acetato o su enantato. Una formulación de acuerdo con la reivindicación 1 CARACTERIZADA PORQUE los niveles de dicha progestina son suficientes como para suprimir la espermatogénesis. Una formulación de acuerdo con la reivindicación 1 CARACTERIZADA PORQUE los niveles de dicha progestina son suficientes como para inducir la oligozoospermia o la azoospermia. Una formulación de acuerdo con la reivindicación 2 CARACTERIZADA PORQUE la dosis del derivado de NET está entre 1 y 10 mg, tal como 1, 2, 3, 4, 5, 6, 7, 8, 9 ó 10 mg. Una formulación de acuerdo con la reivindicación 2 CARACTERIZADA PORQUE la dosis del derivado de NET corresponde a una dosis de 100 a 500 mg para cada administración de 6 semanas, particularmente entre 200 y 400 mg para cada administración de 6 semanas. Una formulación de acuerdo con la reivindicación 1 CARACTERIZADA PORQUE comprende progestina en cantidades suficientes como para disminuir el índice de Pearl hasta no más de 1,4, tal como hasta no más de 1,2, 1,0, 0,8, 0,7, 0,6, 0,5, 0,4, 0,3, 0,2 ó 0, 1.<EMI FILE="01010963_1" ID="1" IMF=JPEG >AA male contraceptive formulation CHARACTERIZED BECAUSE it comprises an effective amount of a progestin, where said progestin possesses both androgenic and estrogenic properties. A formulation according to claim 1 CHARACTERIZED BECAUSE the progestin is norethisterone (NET) or its derivatives, such as its carboxylic esters, in particular its acetate or enanthate. A formulation according to claim 1 CHARACTERIZED BECAUSE the levels of said progestin are sufficient to suppress spermatogenesis. A formulation according to claim 1 CHARACTERIZED BECAUSE the levels of said progestin are sufficient to induce oligozoospermia or azoospermia. A formulation according to claim 2 CHARACTERIZED BECAUSE the dose of the NET derivative is between 1 and 10 mg, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mg. A formulation according to claim 2 CHARACTERIZED BECAUSE the dose of the NET derivative corresponds to a dose of 100 to 500 mg for each 6-week administration, particularly between 200 and 400 mg for each 6-week administration. A formulation according to claim 1 CHARACTERIZED BECAUSE it comprises progestin in amounts sufficient to decrease the Pearl index to no more than 1.4, such as not more than 1.2, 1.0, 0.8, 0, 7, 0.6, 0.5, 0.4, 0.3, 0.2 or 0, 1. <EMI FILE = "01010963_1" ID = "1" MFI = JPEG> A
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00200493 | 2000-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5261637A1 true CO5261637A1 (en) | 2003-03-31 |
Family
ID=37515367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO01010963A CO5261637A1 (en) | 2000-02-15 | 2001-02-13 | MALE ANTI-CONCEPTIVE FORMULATION UNDERSTANDING NORETISTERONE |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR027526A1 (en) |
CO (1) | CO5261637A1 (en) |
PE (1) | PE20011093A1 (en) |
-
2001
- 2001-02-12 PE PE2001000152A patent/PE20011093A1/en not_active Application Discontinuation
- 2001-02-13 CO CO01010963A patent/CO5261637A1/en not_active Application Discontinuation
- 2001-02-14 AR ARP010100654A patent/AR027526A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR027526A1 (en) | 2003-04-02 |
PE20011093A1 (en) | 2001-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GEP20053586B (en) | Selective Androgen Receptor Modulators and Pharmaceutical Compositions Containing the Same | |
HRP20050781B1 (en) | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels | |
AR023346A1 (en) | SUBSTITUTED BICYCLE DERIVATIVE COMPOUNDS AS AGENTS AGAINST CANCER, USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITIONS AND COMPOSITE PREPARATION PROCEDURE | |
AR057060A1 (en) | TANAPROGET COMPOSITIONS CONTAINING ETHYL ESTRADIOL | |
AU7315301A (en) | Compounds and compositions for delivering active agents | |
TW200505454A (en) | Heteroaryl-fused pyrimidinyl compounds as anticancer agents | |
DK1272504T3 (en) | 8. Beta-hydrocarbyl-substituted estradiol for use as selective estrogens | |
NZ600907A (en) | Progestin/estradiol transdermal gel | |
PL1689724T3 (en) | Quinazolinone compounds as anticancer agents | |
GT200000184A (en) | COMPOSITIONS TO FACILITATE THE GROWTH OF SKIN AND METHODS AND ARTICLES THAT USE IT. | |
MXPA01008611A (en) | Compounds and compositions for delivering active agents. | |
MEP38008A (en) | Drospirenone for hormone replacement therapy | |
ES2253423T3 (en) | FORMULATION OF A TESTOSTERONE ESTER FOR HUMAN USE. | |
AR031975A1 (en) | ANALOG COMPOUNDS OF (1R, CIS) -4- (6-AMINO-9H-PURIN-9-IL) -2-CYCLOPENTENE-1-METHANOL, PROCESS FOR PREPARATION, USE IN THE TREATMENT OF VIRAL INFECTIONS, AND PACKING THAT CONTAINS THEM | |
AR065816A1 (en) | ORAL CONTRACEPTIVE REGIME | |
AR026655A1 (en) | NEW STEROIDS WITH ANDROGENIC ACTIVITY AND ITS USE AS MALE ANTINCONCEPTIVES AND TO TREAT ANDROGENIC INSUFFICIENCY | |
TW200612962A (en) | Estriol and estetrol prodrugs | |
CO5261637A1 (en) | MALE ANTI-CONCEPTIVE FORMULATION UNDERSTANDING NORETISTERONE | |
AR045263A1 (en) | METHOD, KIT AND PHARMACEUTICAL COMPOSITION TO TREAT VIRAL INFECTIONS | |
MXPA05010871A (en) | Methods of administering estrogens and progestins. | |
BR0108411A (en) | Male contraceptive formulation comprising norethisterone | |
ES2139602T3 (en) | EYE COMPOSITIONS CONTAINING STEROIDS AND THEIR USE FOR THE TREATMENT OF GLAUCOMA. | |
MX2022000747A (en) | 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases. | |
JP2005532336A5 (en) | ||
PA8474401A1 (en) | 3-KETO TRICYCLIC DERIVATIVES OF 6-0-METHYLERITHROMYCIN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |